Evaluating human epidermal growth factor receptor 2 roles in the efficacy of Tamoxifen treatment in breast cancer, a systematic review.
Sepideh MansouriParisa Mokhtari-HesariFatemeh Naghavi-Al-HosseiniSeyed Afshin SeyednejadKeivan Majidzadeh-AShima Moradi-KalbolandiMarziyeh GhahremanlouLeila FarahmandPublished in: Pharmacological reports : PR (2021)
According to the analysis result, the relapse rate in breast cancer patients who were treated with Tamoxifen depends on the HER2 situation. Despite the limited sample size, it is revealed that Tamoxifen can decrease the relapse rate only in HER2 negative patients.
Keyphrases
- epidermal growth factor receptor
- breast cancer cells
- end stage renal disease
- estrogen receptor
- newly diagnosed
- positive breast cancer
- tyrosine kinase
- ejection fraction
- endothelial cells
- chronic kidney disease
- advanced non small cell lung cancer
- free survival
- prognostic factors
- peritoneal dialysis
- single cell
- patient reported outcomes
- young adults
- patient reported
- replacement therapy
- pluripotent stem cells